ES2120036T3 - Virus recombinantes y su utilizacion en terapia genetica. - Google Patents

Virus recombinantes y su utilizacion en terapia genetica.

Info

Publication number
ES2120036T3
ES2120036T3 ES94913650T ES94913650T ES2120036T3 ES 2120036 T3 ES2120036 T3 ES 2120036T3 ES 94913650 T ES94913650 T ES 94913650T ES 94913650 T ES94913650 T ES 94913650T ES 2120036 T3 ES2120036 T3 ES 2120036T3
Authority
ES
Spain
Prior art keywords
pct
recombinant viruses
genetic therapy
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94913650T
Other languages
English (en)
Inventor
Patrick Benoit
Patrice Denefle
Michel Perricaudet
Sandrine Seguret
Emmanuelle Vigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of ES2120036T3 publication Critical patent/ES2120036T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A VIRUS RECOMBINANTES DEFECTIVOS QUE CONTIENEN UN GEN INSERTADO, LAS COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN ESTOS VIRUS, Y SU UTILIZACION PARA EL TRATAMIENTO O LA PREVENCION DE LAS PATOLOGIAS ASOCIADAS A LAS DISLIPOPROTEINMIAS
ES94913650T 1993-04-30 1994-04-15 Virus recombinantes y su utilizacion en terapia genetica. Expired - Lifetime ES2120036T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9305125A FR2704556B1 (fr) 1993-04-30 1993-04-30 Virus recombinants et leur utilisation en thérapie génique.

Publications (1)

Publication Number Publication Date
ES2120036T3 true ES2120036T3 (es) 1998-10-16

Family

ID=9446605

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94913650T Expired - Lifetime ES2120036T3 (es) 1993-04-30 1994-04-15 Virus recombinantes y su utilizacion en terapia genetica.

Country Status (17)

Country Link
US (2) USRE38556E1 (es)
EP (1) EP0701450B1 (es)
JP (1) JPH08509373A (es)
KR (1) KR100330142B1 (es)
AT (1) ATE169503T1 (es)
AU (1) AU696199B2 (es)
BR (1) BR9406689A (es)
CA (1) CA2161679A1 (es)
DE (1) DE69412486T2 (es)
DK (1) DK0701450T3 (es)
ES (1) ES2120036T3 (es)
FI (1) FI955154A0 (es)
FR (1) FR2704556B1 (es)
GR (1) GR3027660T3 (es)
NO (1) NO954286D0 (es)
WO (1) WO1994025073A1 (es)
ZA (1) ZA942980B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
FR2731229B1 (fr) * 1995-03-02 1997-04-30 Rhone Poulenc Rorer Sa Therapie genique de l'atherosclerose par production de hdl par les lignees monocytaires
US5734699A (en) * 1995-05-04 1998-03-31 Interwave Communications International, Ltd. Cellular private branch exchanges
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
CZ326896A3 (cs) * 1996-11-07 1998-05-13 Milo Olomouc, A. S. Tuk se specifickými protisklerotickými účinky
FR2755699B1 (fr) * 1996-11-08 1998-12-18 Rhone Poulenc Rorer Sa Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
CZ299055B6 (cs) 1996-12-06 2008-04-09 Aventis Pharmaceuticals Inc. Izolovaný polypeptid kódovaný genem podobným genupro lipázu, prostredek mající fosfolipázovou úcinnost, farmaceutický prostredek, izolovaný imunizacní peptid a nukleová kyselina, biologicky aktivní prostredek, vektor, rekombinantní bunka, prostredek
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CA2428114C (en) * 2000-11-10 2013-07-23 Proteopharma Aps Apolipoprotein analogues
US7227014B2 (en) * 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
EP1453536A4 (en) * 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
JP2007518423A (ja) * 2004-01-23 2007-07-12 イントロン、インコーポレイテッド スプライセオソーム仲介型ｒｎａトランススプライシングを使用するアポａ−１及びその変異体の発現
EP1866416A2 (en) * 2005-03-22 2007-12-19 Medstar Health Inc. Delivery systems and methods for diagnosing and treating cardiovascular diseases
JP5407862B2 (ja) * 2006-10-04 2014-02-05 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） ｓｉＲＮＡおよび脂質性４，５−二置換２−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
BR112016025470A2 (pt) 2014-05-02 2017-08-15 Cerenis Therapeutics Holding S A ?hdl terapêutico?

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61135587A (ja) * 1984-12-03 1986-06-23 Norin Suisansyo Shokuhin Sogo Kenkyusho アポリポタン白質ｅ遺伝子およびその調製法
DE3688418T2 (de) * 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
JPS63237795A (ja) * 1987-03-24 1988-10-04 Otsuka Pharmaceut Factory Inc アポリポタンパク質の製造法
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
FR2666813A1 (fr) * 1990-09-18 1992-03-20 Rhone Poulenc Sante Procede microbiologique de preparation de l'apolipoproteine aiv humaine ou de derives de celle-ci.
WO1992007945A1 (en) * 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
WO1993001286A2 (en) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
CA2115742A1 (en) * 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6777977B1 (en) * 2002-05-01 2004-08-17 Actel Corporation Three input field programmable gate array logic circuit configurable as a three input look up table, a D-latch or a D flip-flop
CA2419216C (en) * 2003-02-19 2005-03-01 Jan Nyquist Method and apparatus for joining plastic pipe

Also Published As

Publication number Publication date
KR100330142B1 (ko) 2002-09-27
WO1994025073A1 (fr) 1994-11-10
DE69412486T2 (de) 1999-03-11
BR9406689A (pt) 1996-01-30
FI955154A (fi) 1995-10-27
FI955154A0 (fi) 1995-10-27
AU6572294A (en) 1994-11-21
DK0701450T3 (da) 1999-02-08
USRE38556E1 (en) 2004-07-13
EP0701450A1 (fr) 1996-03-20
AU696199B2 (en) 1998-09-03
ATE169503T1 (de) 1998-08-15
FR2704556B1 (fr) 1995-07-13
CA2161679A1 (fr) 1994-11-10
DE69412486D1 (de) 1998-09-17
GR3027660T3 (en) 1998-11-30
NO954286L (no) 1995-10-26
ZA942980B (en) 1995-01-18
NO954286D0 (no) 1995-10-26
FR2704556A1 (fr) 1994-11-04
US5866551A (en) 1999-02-02
JPH08509373A (ja) 1996-10-08
EP0701450B1 (fr) 1998-08-12

Similar Documents

Publication Publication Date Title
ES2120036T3 (es) Virus recombinantes y su utilizacion en terapia genetica.
ATE209686T1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
HK1025737A1 (en) Treatment of multiple sclerosis through ingestion of copolymer-1
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DK1095061T3 (da) Peptider baseret på sekvensen af humant lactoferring og deres anvendelse
ATE179211T1 (de) Menschliche il-3-varianten
IL114904A0 (en) Adenovirus comprising a gene encoding glutathione peroxidase
GR3026600T3 (en) Human il-4 mutant proteins.
DE69535673D1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
HUP9801214A2 (hu) Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk
O'Connell et al. Distribution and toxicity resulting from adenoviral vector administration to a single salivary gland in adult rats
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
KR960703432A (ko) 신경퇴행성 질환의 치료를 위한 제약학적 조성물 및 이들의 사용방법(pharmaceutical compositions and their use, namely for the treatment of neurodegenerative diseases)
FI960333A (fi) Tryptaasi-inhibiittori
BR0009666A (pt) Adenovìrus recombinante e mutante derivado de adenovìrus bovino tipo 1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701450

Country of ref document: ES